Overview
Anjelisa Hasibuan practices practicing medicine in Medan, Indonesia.
Their clinical expertise encompasses HER-2 Positive Breast Cancer, Breast Cancer, and Dehydration.
They are actively involved in clinical research, co-authoring 22 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Anjelisa Z. Hasibuan
Is Anjelisa Z. Hasibuan a top-rated expert for HER-2 Positive Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Anjelisa Z. Hasibuan is classified as an Experienced expert for HER-2 Positive Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Anjelisa Z. Hasibuan participate in research or clinical trials?
Yes. Anjelisa Z. Hasibuan has published 22 articles and abstracts on conditions like HER-2 Positive Breast Cancer. You can view a list of Anjelisa Z. Hasibuan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Breast CancerHasibuan isExperienced. Learn about Breast Cancer.
- DehydrationHasibuan isExperienced. Learn about Dehydration.
- HER-2 Positive Breast CancerHasibuan isExperienced. Learn about HER-2 Positive Breast Cancer.